Cisplatin, Methotrexate and Vinblastine Plus Surgical Restaging for Patients with Advanced Transitional Cell Carcinoma of the Urothelium
Authors:
- 1 July 1993
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 150 (1) , 65-69
Abstract
Chemotherapy with cisplatin, methotrexate and vinblastine (CMV) is active in advanced transitional cell carcinoma of the urothelium. Aggressive surgical resection of residual disease following responses produced by CMV was incorporated into a combined modality approach. Between 1982 and 1990, 64 patients were entered into the study. Of 55 patients evaluable for response 11 (20%) had a pathological complete response, 14 (25%) achieved a complete response following resection of residual disease and 5 (9%) whose disease was not surgically restaged had a clinical complete response. The overall complete response rate was 55%. Patients with liver, lung or bone involvement had significantly decreased survival compared to patients without visceral disease (p = 0.002). With a median followup exceeding 50 months, 14 patients (22% of all patients entered into the study) were free of disease at 23 to 98+ months. There were no deaths related to treatment. CMV produced high rates of response in patients with advanced disease, including those with distant metastases. Surgical resection of residual disease following responses produced by chemotherapy proved to be feasible, without treatment related mortality, and may have prolonged survival in selected cases.Keywords
This publication has 11 references indexed in Scilit:
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1992
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of Clinical Oncology, 1990
- Biology and Management of Bladder CancerNew England Journal of Medicine, 1990
- Phase III Comparison of Cisplatin Alone Versus Cisplatin, Doxorubicin and Cyclophosphamide in the Treatment of Bladder (Urothelial) Cancer: A Southeastern Cancer Study Group TrialJournal of Urology, 1987
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- Regional Lymph Node Metastasis From Bladder CancerJournal of Urology, 1981
- A Phase 2 Study of Cis‐platinum in Patients with Recurrent Bladder CarcinomaBritish Journal of Urology, 1981
- Cis-Diamminedichloride Platinum II in the Treatment of Abvanced Bladder CancerJournal of Urology, 1980
- Cis-Diamminebichloroplatinum as a Therapeutic Agent in Metastatic Transitional Cell CarcinomaJournal of Urology, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958